Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Unblinded, Comparative, Randomized Study of Influenza A/H1N1 2009 Resistance in Patients With Standard and Double Dose Oseltamivir Treatment.

Next Previous
Trial Profile

An Unblinded, Comparative, Randomized Study of Influenza A/H1N1 2009 Resistance in Patients With Standard and Double Dose Oseltamivir Treatment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 08 Jul 2011 Additional lead trial center (National Centre for Immunisation Research and Surveillance) added as reported by Australian New Zealand Clinical Trials Registry.
  • 08 Jul 2011 New source added and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12610000004066).
  • 18 Jan 2011 Actual end date (Dec 2010 ) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top